The outlook of companies tied to flagship drugs like Viagra presents a complex investment landscape . While the initial surge of copyright, fueled by Viagra's unprecedented popularity, generated substantial returns, the loss of exclusivity in key regions has introduced substantial volatility. Investors are now facing the effect of rival medications